These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 28299661)

  • 1. Molecular Basis and Targeted Inhibition of CBFβ-SMMHC Acute Myeloid Leukemia.
    Castilla LH; Bushweller JH
    Adv Exp Med Biol; 2017; 962():229-244. PubMed ID: 28299661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HDAC1 Is a Required Cofactor of CBFβ-SMMHC and a Potential Therapeutic Target in Inversion 16 Acute Myeloid Leukemia.
    Richter LE; Wang Y; Becker ME; Coburn RA; Williams JT; Amador C; Hyde RK
    Mol Cancer Res; 2019 Jun; 17(6):1241-1252. PubMed ID: 30814129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical analysis of CBFbeta-SMMHC protein reveals a unique nuclear localization in acute myeloid leukemia with inv(16)(p13q22).
    Zhao W; Claxton DF; Medeiros LJ; Lu D; Vadhan-Raj S; Kantarjian HM; Nguyen MH; Bueso-Ramos CE
    Am J Surg Pathol; 2006 Nov; 30(11):1436-44. PubMed ID: 17063086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute myeloid leukemia with t(16;16) (p13;q22) showing a new CBFB-MYH11 fusion transcript associated with an atypical leukemic blasts morphology.
    Albano F; Anelli L; Zagaria A; Coccaro N; Tota G; Impera L; Minervini CF; Cellamare A; Delia M; Minervini A; Casieri P; Specchia G
    Hum Pathol; 2014 Mar; 45(3):643-7. PubMed ID: 24342433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FLT3-ITD cooperates with inv(16) to promote progression to acute myeloid leukemia.
    Kim HG; Kojima K; Swindle CS; Cotta CV; Huo Y; Reddy V; Klug CA
    Blood; 2008 Feb; 111(3):1567-74. PubMed ID: 17967943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methylation-independent silencing of the tumor suppressor INK4b (p15) by CBFbeta-SMMHC in acute myelogenous leukemia with inv(16).
    Markus J; Garin MT; Bies J; Galili N; Raza A; Thirman MJ; Le Beau MM; Rowley JD; Liu PP; Wolff L
    Cancer Res; 2007 Feb; 67(3):992-1000. PubMed ID: 17283131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging therapies for inv(16) AML.
    Surapally S; Tenen DG; Pulikkan JA
    Blood; 2021 May; 137(19):2579-2584. PubMed ID: 33821975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemical biology. A small-molecule inhibitor of the aberrant transcription factor CBFβ-SMMHC delays leukemia in mice.
    Illendula A; Pulikkan JA; Zong H; Grembecka J; Xue L; Sen S; Zhou Y; Boulton A; Kuntimaddi A; Gao Y; Rajewski RA; Guzman ML; Castilla LH; Bushweller JH
    Science; 2015 Feb; 347(6223):779-84. PubMed ID: 25678665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting binding partners of the CBFβ-SMMHC fusion protein for the treatment of inversion 16 acute myeloid leukemia.
    Richter L; Wang Y; Hyde RK
    Oncotarget; 2016 Oct; 7(40):66255-66266. PubMed ID: 27542261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cbfbeta reduces Cbfbeta-SMMHC-associated acute myeloid leukemia in mice.
    Heilman SA; Kuo YH; Goudswaard CS; Valk PJ; Castilla LH
    Cancer Res; 2006 Dec; 66(23):11214-8. PubMed ID: 17145866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Classifying AML patients with inv(16) into high-risk and low-risk relapsed patients based on peritransplantation minimal residual disease determined by CBFβ/MYH11 gene expression.
    Xiaosu Z; Leqing C; Yazhen Q; Yu W; Xiaohui Z; Lanping X; Xiaojun H; Yingjun C
    Ann Hematol; 2019 Jan; 98(1):73-81. PubMed ID: 30159599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization and use of an antibody detecting the CBFbeta-SMMHC fusion protein in inv(16)/t(16;16)-associated acute myeloid leukemias.
    Viswanatha DS; Chen I; Liu PP; Slovak ML; Rankin C; Head DR; Willman CL
    Blood; 1998 Mar; 91(6):1882-90. PubMed ID: 9490670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gata2 deficiency delays leukemogenesis while contributing to aggressive leukemia phenotype in Cbfb-MYH11 knockin mice.
    Saida S; Zhen T; Kim E; Yu K; Lopez G; McReynolds LJ; Liu PP
    Leukemia; 2020 Mar; 34(3):759-770. PubMed ID: 31624376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RUNX1 and CBFβ Mutations and Activities of Their Wild-Type Alleles in AML.
    Hyde RK; Liu P; Friedman AD
    Adv Exp Med Biol; 2017; 962():265-282. PubMed ID: 28299663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. c-Myc overcomes cell cycle inhibition by CBFbeta-SMMHC, a myeloid leukemia oncoprotein.
    Bernardin F; Yang Y; Civin CI; Friedman AD
    Cancer Biol Ther; 2002; 1(5):492-6. PubMed ID: 12496475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RUNX1 and CBFβ-SMMHC transactivate target genes together in abnormal myeloid progenitors for leukemia development.
    Zhen T; Cao Y; Ren G; Zhao L; Hyde RK; Lopez G; Feng D; Alemu L; Zhao K; Liu PP
    Blood; 2020 Nov; 136(21):2373-2385. PubMed ID: 32929473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proleukemic RUNX1 and CBFbeta mutations in the pathogenesis of acute leukemia.
    Engel ME; Hiebert SW
    Cancer Treat Res; 2010; 145():127-47. PubMed ID: 20306249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CBFβ-SMMHC Inhibition Triggers Apoptosis by Disrupting MYC Chromatin Dynamics in Acute Myeloid Leukemia.
    Pulikkan JA; Hegde M; Ahmad HM; Belaghzal H; Illendula A; Yu J; O'Hagan K; Ou J; Muller-Tidow C; Wolfe SA; Zhu LJ; Dekker J; Bushweller JH; Castilla LH
    Cell; 2018 Jun; 174(1):172-186.e21. PubMed ID: 29958106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rare CBFB-MYH11 fusion transcripts in AML with inv(16)/t(16;16) are associated with therapy-related AML M4eo, atypical cytomorphology, atypical immunophenotype, atypical additional chromosomal rearrangements and low white blood cell count: a study on 162 patients.
    Schnittger S; Bacher U; Haferlach C; Kern W; Haferlach T
    Leukemia; 2007 Apr; 21(4):725-31. PubMed ID: 17287858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical implications of additional chromosomal abnormalities in adult acute myeloid leukemia with inv (16)/t(16;16)/CBFB::MYH11.
    Gao J; Santana-Santos L; Fu L; Alvey E; Chen Q; Wolniak K; Xia Z; Aqil B; Behdad A; Ji P; Sukhanova M; Abaza Y; Altman JK; Chen YH; Lu X
    Eur J Haematol; 2024 Jun; 112(6):964-974. PubMed ID: 38388794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.